7UT0
Human DDAH-1, apo form
Summary for 7UT0
| Entry DOI | 10.2210/pdb7ut0/pdb |
| Related | 7USZ |
| Descriptor | N(G),N(G)-dimethylarginine dimethylaminohydrolase 1, 1,2-ETHANEDIOL (3 entities in total) |
| Functional Keywords | cardiovascular enzyme, proton pump inhibitors, esomeprazole, hydrolase |
| Biological source | Homo sapiens (human) |
| Total number of polymer chains | 2 |
| Total formula weight | 62443.58 |
| Authors | Smith, C.A.,Ghebre, Y.T. (deposition date: 2022-04-26, release date: 2022-05-18, Last modification date: 2023-10-18) |
| Primary citation | Smith, C.A.,Ebrahimpour, A.,Novikova, L.,Farina, D.,Bailey, A.O.,Russell, W.K.,Jain, A.,Saltzman, A.B.,Malovannaya, A.,Prasad, B.V.V.,Hu, L.,Ghebre, Y.T. Esomeprazole covalently interacts with the cardiovascular enzyme dimethylarginine dimethylaminohydrolase: Insights into the cardiovascular risk of proton pump inhibitors. Biochim Biophys Acta Gen Subj, 1866:130149-130149, 2022 Cited by PubMed Abstract: Proton pump inhibitors (PPIs) are widely prescribed drugs for the treatment of gastroesophageal reflux disease (GERD). Several meta-analysis studies have reported associations between prolonged use of PPIs and major adverse cardiovascular events. However, interaction of PPIs with biological molecules involved in cardiovascular health is incompletely characterized. Dimethylarginine dimethylaminohydrolase (DDAH) is a cardiovascular enzyme expressed in cardiomyocytes, and other somatic cell types in one of two isotypes (DDAH1 and DDAH2) to metabolize asymmetric dimethylarginine (ADMA); a cardiovascular risk factor and competitive inhibitor of nitric oxide synthases (NOSs). PubMed: 35472493DOI: 10.1016/j.bbagen.2022.130149 PDB entries with the same primary citation |
| Experimental method | X-RAY DIFFRACTION (1.68 Å) |
Structure validation
Download full validation report
